Voyager Therapeutics' (VYGR) Buy Rating Reaffirmed at HC Wainwright

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $30.00 target price on the stock.

A number of other equities research analysts also recently weighed in on the stock. Canaccord Genuity Group reiterated a "buy" rating and issued a $14.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Cantor Fitzgerald restated an "overweight" rating on shares of Voyager Therapeutics in a research report on Wednesday. Wells Fargo & Company set a $10.00 price objective on shares of Voyager Therapeutics and gave the stock an "overweight" rating in a research report on Wednesday. Citigroup initiated coverage on shares of Voyager Therapeutics in a research note on Monday, December 2nd. They set a "buy" rating and a $12.00 price objective on the stock. Finally, StockNews.com cut shares of Voyager Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, December 13th. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $15.08.

Remove Ads

Voyager Therapeutics Stock Up 2.3 %

VYGR opened at $4.06 on Thursday. Voyager Therapeutics has a 12-month low of $3.56 and a 12-month high of $10.66. The business has a 50 day moving average of $4.95 and a 200-day moving average of $5.87. The stock has a market cap of $221.78 million, a price-to-earnings ratio of 5.72 and a beta of 0.99.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.24). Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $4.39 million during the quarter, compared to the consensus estimate of $16.58 million. During the same quarter last year, the company posted $1.25 EPS. As a group, analysts expect that Voyager Therapeutics will post -0.91 earnings per share for the current year.

Insider Activity at Voyager Therapeutics

In other news, COO Robin Swartz sold 6,500 shares of the company's stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the transaction, the chief operating officer now owns 112,328 shares of the company's stock, valued at $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders sold a total of 10,778 shares of company stock valued at $58,548 in the last quarter. Insiders own 4.53% of the company's stock.

Hedge Funds Weigh In On Voyager Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in VYGR. Empowered Funds LLC lifted its holdings in Voyager Therapeutics by 5.4% during the 3rd quarter. Empowered Funds LLC now owns 44,809 shares of the company's stock worth $262,000 after buying an additional 2,278 shares during the period. Rhumbline Advisers lifted its stake in shares of Voyager Therapeutics by 3.4% in the fourth quarter. Rhumbline Advisers now owns 71,497 shares of the company's stock worth $405,000 after acquiring an additional 2,354 shares during the period. Wells Fargo & Company MN boosted its holdings in Voyager Therapeutics by 3.7% in the fourth quarter. Wells Fargo & Company MN now owns 66,718 shares of the company's stock valued at $378,000 after acquiring an additional 2,400 shares during the last quarter. Picton Mahoney Asset Management increased its position in Voyager Therapeutics by 71.1% during the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company's stock valued at $33,000 after purchasing an additional 2,444 shares during the period. Finally, Tower Research Capital LLC TRC raised its holdings in Voyager Therapeutics by 133.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock worth $31,000 after purchasing an additional 3,077 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.